Author: Vineet D. Menachery; Lisa E. Gralinski; Hugh D. Mitchell; Kenneth H. Dinnon; Sarah R. Leist; Boyd L. Yount; Eileen T. McAnarney; Rachel L. Graham; Katrina M. Waters; Ralph S. Baric
Title: Combination attenuation offers strategy for live-attenuated coronavirus vaccines Document date: 2018_4_28
ID: 3t75dbb7_9
Snippet: While the SARS-and to a lesser extent the MERS-CoV outbreaks have been mostly 44 contained, this limitation has been primarily due to effective public health measures and the 45 delayed transmissibility of the viruses until after symptomatic disease (5). Standard antiviral 46 treatments with type I IFN or traditional nucleoside analogs like ribavirin have shown minimal 47 success against either epidemic strain (6). While several antibodies have b.....
Document: While the SARS-and to a lesser extent the MERS-CoV outbreaks have been mostly 44 contained, this limitation has been primarily due to effective public health measures and the 45 delayed transmissibility of the viruses until after symptomatic disease (5). Standard antiviral 46 treatments with type I IFN or traditional nucleoside analogs like ribavirin have shown minimal 47 success against either epidemic strain (6). While several antibodies have been designed 48 against SARS-and MERS-CoV, their efficacy has been found to be strain specific and may offer 49 minimal protection against heterologous or unrelated coronaviruses, especially under 50 therapeutic conditions (4, 7). Other drugs, targeting conserved CoV activities, have had either 51 marginal efficacy in vivo or offer only a small window for treatment during early infection (8, 9) .
Search related documents:
Co phrase search for related documents- cov activity and less extent: 1, 2
- cov activity and MERS cov: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78
- cov activity and MERS cov outbreak: 1, 2
- cov activity and nucleoside analog: 1, 2, 3, 4, 5, 6, 7, 8, 9
- cov activity and public health: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- cov activity and specific strain: 1
- cov activity and symptomatic disease: 1, 2
- early infection and epidemic strain: 1, 2
- early infection and less extent: 1, 2
- early infection and MERS cov: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- early infection and MERS cov outbreak: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- early infection and public health: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- early infection and specific strain: 1, 2, 3, 4, 5, 6, 7
- early infection and symptomatic disease: 1, 2, 3, 4, 5, 6
- epidemic strain and MERS cov: 1, 2
- epidemic strain and public health: 1, 2, 3, 4, 5, 6
- epidemic strain and specific strain: 1, 2, 3, 4
Co phrase search for related documents, hyperlinks ordered by date